Talis Biomedical Corporation
TLIS
$1.60
-$0.08-4.76%
| Weiss Ratings | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.47 | |||
| Price History | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.76% | |||
| 30-Day Total Return | 1.91% | |||
| 60-Day Total Return | -13.04% | |||
| 90-Day Total Return | -3.61% | |||
| Year to Date Total Return | -5.88% | |||
| 1-Year Total Return | -80.61% | |||
| 2-Year Total Return | -81.04% | |||
| 3-Year Total Return | -93.42% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -83.33% | |||
| 52-Week Low % Change | 16.79% | |||
| Price | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.60 | |||
| 52-Week Low Price | $1.37 | |||
| 52-Week Low Price (Date) | Sep 04, 2024 | |||
| 52-Week High Price (Date) | May 07, 2024 | |||
| Valuation | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.92M | |||
| Enterprise Value | -38.15M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -28.02 | |||
| Earnings Per Share Growth | -40.91% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 7.15 | |||
| Price/Book (Q) | 0.06 | |||
| Enterprise Value/Revenue (TTM) | -93.50 | |||
| Price | $1.60 | |||
| Enterprise Value/EBITDA (TTM) | 0.77 | |||
| Enterprise Value/EBIT | 0.76 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.82M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 433 3000 | |||
| Address | 1375 West Fulton Market Chicago, IL 60607 | |||
| Website | talisbio.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -12,291.91% | |||
| Profit Margin | -12,506.37% | |||
| Management Effectiveness | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -32.02% | |||
| Return on Equity | -- | |||
| Income Statement | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 408.00K | |||
| Total Revenue (TTM) | 408.00K | |||
| Revenue Per Share | $0.22 | |||
| Gross Profit (TTM) | -20.09M | |||
| EBITDA (TTM) | -49.38M | |||
| EBIT (TTM) | -50.15M | |||
| Net Income (TTM) | -51.03M | |||
| Net Income Avl. to Common (TTM) | -51.03M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 41.14% | |||
| EPS Diluted (TTM) | -28.02 | |||
| EPS Diluted Growth (Q YOY) | 41.31% | |||
| Balance Sheet | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 59.87M | |||
| Cash Per Share (Q) | $32.85 | |||
| Total Current Assets (Q) | 63.60M | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | 48.63M | |||
| Current Ratio (Q) | 7.760 | |||
| Book Value Per Share (Q) | $26.68 | |||
| Total Assets (Q) | 72.70M | |||
| Total Current Liabilities (Q) | 8.20M | |||
| Total Debt (Q) | 18.80M | |||
| Total Liabilities (Q) | 24.07M | |||
| Total Common Equity (Q) | 48.62M | |||
| Cash Flow | TLIS - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 137.00K | |||
| Cash from Financing (TTM) | 2.00K | |||
| Net Change in Cash (TTM) | -40.12M | |||
| Levered Free Cash Flow (TTM) | -28.29M | |||
| Cash from Operations (TTM) | -40.26M | |||
